ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$6.76
-0.32 (-4.52%)
Open$7.08
Previous Close$7.08
Day High$7.21
Day Low$6.58
52W High$24.17
52W Low$5.85
Volume—
Avg Volume487.1K
Market Cap206.07M
P/E Ratio—
EPS$-2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+290.7% upside
Current
$6.76
$6.76
Target
$26.41
$26.41
$16.23
$26.41 avg
$33.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 74.82M | 101.70M | 31.39M |
| Net Income | -59,999,289 | -73,398,613 | -5,088,256 |
| Profit Margin | -80.2% | -76.2% | -16.2% |
| EBITDA | -66,795,762 | -86,252,513 | -7,015,778 |
| Free Cash Flow | — | — | -5,929,972 |
| Rev Growth | -26.4% | -26.4% | +5.3% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |